Mangoceuticals announced the release and availability of ‘PRIME’ by MangoRx, Powered by Kyzatrex bringing the FDA-approved oral testosterone replacement therapy treatment to consumers across the U.S via its proprietary telehealth platform. MangoRx intends to market PRIME to those male individuals who are both a) currently on some alternative form of TRT treatment, such as topicals and other invasive injectables or pellets, and b) those experiencing common symptoms associated with low testosterone and seeking an immediate TRT treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MGRX:
- MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
- Mangoceuticals launches direct-to-clinics sales division
- Mangoceuticals offers one year supply of Mango ED to San Francisco players
- Mangoceuticals to offer one year supply of Mango ED to Big Game losing team
- MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS